You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


AZ builds case for fixed-dose albuterol and budesonide combo in asthma

AstraZeneca has revealed positive results from two Phase III trials of the fixed-dose combination of albuterol and budesonide – also known as PT027 – in patients with moderate-to-severe asthma.